Pathophysiology And Rational Pharmacotherapy Of Myocardial Ischemia

Ischemie heart disease is still the most frequent cause of death in the western world. There have been significant achievements in diagnostic procedures as well as in the medical, invasive, and surgiealtreatment ofischemieheart disease inrecent years. A variety ofdrugs are availablefor the pharmacotherapyofischemieheart disease, par ticularly nitrates, ß-blockers, and calcium-antagonists which are used as mono therapy or in various combinations. However, the selection of patients for a certain treatment, as weIl as the optimization of an individual treatment are still largely empirical. On the other hand, the recent advances in experimental cardiology emphasize the extremely complex and dynamie scenario of ischemic heart disease, involving endothelial damage, coagulation processes, metabolie and morphologie derangements, coronary constrictor mechanisms, blood flow redistribution, arrhythmogenesis, contraetile dysfunction during ischemia and reperfusion, and finally lack or presence of pain perception. Therefore, it appears desirable to close the gap between experimental and clinical cardiology and, thus, to provide a pathophysiologieal basis for rational cliniealdecisions with respect to diagnostic and therapeutic procedures. The idea for this book arose during the preparation of a seminar series on experi mental cardiology, when I found it diffieultto collect the pertinentinformation from textbooks of cardiology, physiology, pathology, and pharmacology, as well as from numerous review and original artieies on specifictopies. I am now very grateful that expert cliniealand experimental colleagues from around the world have joined me in the effort to provide a comprehensive textbook on the pathophysiology of myocar dial ischemia and its rational pharmacotherapy.

The Pathophysiology and Pharmacotherapy of Myocardial Infarction deals with the advances in the pathophysiology and pharmacotherapy of acute myocardial infarction and related complications. This book covers two major consequences—cardiac muscle dysfunction and cardiac electrical dysfunction. This text begins by reviewing the controversy surrounding the pathogenetic mechanisms of atheroma formation and its potential reversibility, including the status of coronary risk factors and benefits of primary prevention. The pathophysiologic mechanisms of pump failure and the current approach to its management are then deliberated, followed by a discussion on the rational use of vasodilators in post-infarction heart failure and pharmacotherapy of cardiogenic shock. The rationale for the interest in the role of coronary vasospasm and thrombolytic therapy for acute myocardial infarction is also covered. This publication concludes by reviewing the approaches for the management of post-infarction ventricular tachyarrhythmias and concept of secondary prevention of sudden cardiac death. This compilation is valuable to medical students, primary care physicians, and cardiovascular specialists.

This book explains the pharmacological relationships between the various systems in the human body. It offers a comprehensive overview of the pharmacology concerning the autonomic, central, and peripheral nervous systems. Presenting up-to-date information on chemical mediators and their significance, it highlights the therapeutic aspects of several diseases affecting the cardiovascular, renal, respiratory, gastrointestinal, endocrinal, and hematopoietic systems. The book also includes drug therapy for microbial and neoplastic diseases. It also comprises sections on immunopharmacology, dermatological, and ocular pharmacology providing valuable insights into these emerging and recent topics. Covering the diverse groups of drugs acting on different systems, the book reviews their actions, clinical uses, adverse effects, interactions, and subcellular mechanisms of action. It is divided into 11 parts, subdivided into several chapters that evaluate the basic pharmacological principles that govern the different types of body systems. This book is intended for academicians, researchers, and clinicians in industry and academic institutions in pharmaceutical, pharmacological sciences, pharmacy, medical sciences, physiology, neurosciences, biochemistry, molecular biology and other allied health sciences.

The spectrum of unstable coronary syndromes has been the object of steadily increasing research particularly in respect of novel diagnostic and treatment modalities. Although the WHO criteria for the diagnosis of acute myocardial infarction have been known for decades, there is still much debate as to the proper use of these, especially the handling of biochemical markers. Traditional enzymes have limitations in diagnostic power and new markers have unclarified applicability with regard to standardisation of assays and decision limits. Furthermore, the growing understanding of the conception of minimal myocardial damage in the borderzone between unstable angina pectoris and myocardial infarction necessitates refinement in the definitions of the various entities within the kaleidoscope of acute myocardial ischaemia. There has been a strong impetus within the European Society of Cardiology to present this subject to a broad audience of cardiologists, and as a consequence the theme of biochemical markers has become an important constituent of the Education and Training Programmes of the Society. This book has fundamental implications for the overall comprehension of this complex area. This book on myocardial damage, compiled by international experts, will truly appeal to the basic scientist as well as the clinician searching for updated knowledge of the pathophysiology and risk stratification of unstable coronary syndromes.

First multi-year cumulation covers six years: 1965-70.

The present book covers the basic principles of cardiovascular physiology, pathophysiology and advanced pharmacology with particular emphasis on cellular mechanisms of drug action. It provides an update on the progress made in several aspects of cardiovascular diseases so that it might kindle scientists and clinicians alike in furthering basic and translational research. In addition, the book is expected to fill imperative gaps in understanding and optimally treating cardiovascular disease.